This thesis describes the treatment of exudative Age-Related Macular Degeneration (ARMD) with bevacizumab. The main object of the thesis was to evaluate the viability of less frequent bevacizumab dosage regiments. Furthermore, the reactivation interval of CNV was observed, and we delved deeper into a specific kind of CNV and its characteristics using a novel diagnostic technique. Our studies showed that treatment of exudative ARMD with bevacizumab either fixed-dose or on-demand can be extended from 4 weeks to up to 8 weeks.